New obesity drug HM15275 enters Mid-Stage trial

NCT ID NCT07205900

Ongoing Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests an experimental drug called HM15275 for weight loss in 267 adults who are obese or overweight but do not have diabetes. Participants receive either the drug or a placebo as a weekly injection for 36 weeks. The main goal is to see how much body weight changes from the start to the end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HM15275 (injectable drug)
What this could lead to: If successful, this could lead to a new weight-loss medication for people with obesity or overweight.
What could go wrong: This is an early phase 2 trial with only 267 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE OBESITY

Contacts and locations

Locations

Accellacare of Bristol-PAC of Tennessee

Bristol, Tennessee, 37620, United States
Accellacare of Cary - Cary Medical Group

Cary, North Carolina, 27511, United States
Accellacare of Charleston

Mt. Pleasant, South Carolina, 29464, United States
Accellacare of Duly - Duly Oak Lawn

Oak Lawn, Illinois, 60453, United States
Accellacare of Hickory

Hickory, North Carolina, 28601, United States
Accellacare of McFarland

Ames, Iowa, 50010, United States
Accellacare of Piedmont - Piedmont HealthCare

Statesville, North Carolina, 28626, United States
Accellacare of Wilmington, LLC

Wilmington, North Carolina, 28401, United States
Accellacare of Winston Salem

Winston-Salem, North Carolina, 27103, United States
Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C.

Bristol, Tennessee, 37620, United States
ProSciento Inc

Chula Vista, California, 91911, United States
Raleigh Medical Group, P.A.

Raleigh, North Carolina, 27609, United States
Texas Clinical Research Institute

Arlington, Texas, 76012, United States
Velocity Clinical Research, Dallas

Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.